Suspension of trading
Exscientia plc Stock
Stocks
EXAI
US30223G1022
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
00:00:00 20/11/2024 +03
|
5-day change | 1st Jan Change | ||
| 4.840 USD | +3.20% |
|
-.--% | - |
| 21/11/24 | Exscientia plc(NasdaqGS:EXAI) dropped from S&P Global BMI Index | CI |
| 20/11/24 | Recursion Pharmaceuticals, Exscientia Complete Business Combination | MT |
| Market Cap | 500M 667M 583M 548M 938M 63.75B 938M 6.57B 2.54B 32.56B 2.5B 2.45B 105B | P/E 2022 |
-4.55x | P/E 2023 | -4.28x |
|---|---|---|---|---|---|
| Enterprise Value | 156M 208M 182M 171M 292M 19.86B 292M 2.05B 790M 10.14B 780M 763M 32.7B | EV / Sales 2022 |
1.9x | EV / Sales 2023 | 14.2x |
| Free-Float |
36.87% | Yield 2022 * |
-
| Yield 2023 | - |
| 1 day | +3.20% |
| 3 years | 3.8 | 7.91 | |
| 5 years | 3.8 | 30.38 | |
| 10 years | 3.8 | 30.38 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Tech/Sci/R&D Officer | 61 | 06/06/2024 | |
| Chief Tech/Sci/R&D Officer | - | 01/05/2022 | |
John Overington
CTO | Chief Tech/Sci/R&D Officer | - | 01/05/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Mario Polywka
BRD | Director/Board Member | 63 | 28/09/2017 |
Robert Ghenchev
BRD | Director/Board Member | 43 | 01/05/2020 |
Elizabeth Crain
CHM | Chairman | 61 | 12/02/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +3.20% | -.--% | -.--% | -1.02% | 633M | ||
| +2.55% | +5.35% | +3.61% | +32.02% | 46.68B | ||
| +0.08% | +1.66% | +44.26% | +35.60% | 44.42B | ||
| +0.05% | -5.97% | +342.95% | +532.74% | 41.32B | ||
| +0.66% | +4.03% | +10.07% | +96.02% | 41.58B | ||
| -1.60% | -0.17% | +9.73% | +43.63% | 30.14B | ||
| +0.96% | +5.84% | +26.39% | +161.70% | 17.42B | ||
| -0.01% | -10.32% | - | - | 15.6B | ||
| +1.15% | +9.42% | +26.21% | +42.84% | 15.54B | ||
| -1.08% | +24.08% | -12.52% | - | 14.08B | ||
| Average | +0.57% | +3.05% | +50.08% | +117.94% | 26.74B | |
| Weighted average by Cap. | +0.43% | +1.94% | +70.32% | +142.50% |
| 2022 | 2023 | |
|---|---|---|
| Net sales | 27.22M 36.32M 31.74M 29.83M 51.09M 3.47B 51.1M 358M 138M 1.77B 136M 133M 5.72B | 20.08M 26.79M 23.41M 22M 37.68M 2.56B 37.69M 264M 102M 1.31B 101M 98.4M 4.22B |
| Net income | -119M -158M -138M -130M -223M -15.14B -223M -1.56B -603M -7.73B -595M -582M -24.93B | -146M -195M -170M -160M -274M -18.62B -274M -1.92B -741M -9.51B -731M -715M -30.65B |
| Net Debt | -492M -656M -574M -539M -923M -62.74B -923M -6.47B -2.5B -32.04B -2.46B -2.41B -103B | -344M -459M -401M -377M -646M -43.89B -646M -4.53B -1.75B -22.41B -1.72B -1.69B -72.26B |
Employees
483
- Stock Market
- Stocks
- EXAI Stock
Select your edition
All financial news and data tailored to specific country editions
















